Q linea AB Total Assets
Q linea AB total assets. Based on the latest financial reports, Q linea AB (QLINEA) holds total assets worth Skr333.61 Million SEK (≈ $35.90 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Q linea AB (QLINEA) total market value for the company's overall valuation and market capitalisation.
Total Assets of Q linea AB (2015–2025)
Total assets of Q linea AB from 2015 to 2025. This chart illustrates how Q linea AB's total assets have evolved over time, based on quarterly financial data. See Q linea AB (QLINEA) share price today for real-time trading data and today's change.
Q linea AB - Asset Composition Analysis
Q linea AB Total Assets Breakdown (December 2025)
Q linea AB total assets breakdown as of December 2025. Q linea AB's total assets of Skr333.61 Million consist of 89.2% current assets and 10.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr258.11 Million | 69.8% |
| Accounts Receivable | Skr38.19 Million | 10.3% |
| Inventory | Skr30.68 Million | 8.3% |
| Property, Plant & Equipment | Skr32.72 Million | 8.9% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr4.89 Million | 1.3% |
Asset Composition Trend (2015–2025)
This chart illustrates how Q linea AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Q linea AB current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Q linea AB's current assets represent 89.2% of total assets in 2025, an increase from 59.7% in 2015.
- Cash Position: Cash and equivalents constituted 69.8% of total assets in 2025, up from 9.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 16.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 69.8% of total assets.
Q linea AB Competitors by Total Assets
Key competitors of Q linea AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
T&L Co. Ltd
KQ:340570
|
Korea | ₩253.22 Billion |
|
Paxman AB
ST:PAX
|
Sweden | Skr487.65 Million |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
ORTOMA AB B
F:82Y
|
Germany | €161.34 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
Q linea AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.48 | 5.04 | 5.92 |
| Quick Ratio | 9.43 | 3.90 | 5.57 |
| Cash Ratio | 0.00 | 2.34 | 0.74 |
| Working Capital | Skr267.61 Million | Skr117.21 Million | Skr320.68 Million |
Q linea AB - Advanced Valuation Insights
This section examines the relationship between Q linea AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 149.8% |
| Total Assets | Skr369.67 Million |
| Market Capitalization | $29.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Q linea AB's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Q linea AB's assets grew by 149.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Q linea AB (2015–2025)
The table below shows the annual total assets of Q linea AB from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr369.67 Million ≈ $39.78 Million |
+149.79% |
| 2024-12-31 | Skr147.99 Million ≈ $15.93 Million |
-36.20% |
| 2023-12-31 | Skr231.98 Million ≈ $24.96 Million |
+11.86% |
| 2022-12-31 | Skr207.39 Million ≈ $22.32 Million |
-55.56% |
| 2021-12-31 | Skr466.63 Million ≈ $50.22 Million |
+13.20% |
| 2020-12-31 | Skr412.23 Million ≈ $44.36 Million |
+10.10% |
| 2019-12-31 | Skr374.41 Million ≈ $40.29 Million |
-30.55% |
| 2018-12-31 | Skr539.07 Million ≈ $58.01 Million |
+2830.20% |
| 2017-12-31 | Skr18.40 Million ≈ $1.98 Million |
+9.11% |
| 2016-12-31 | Skr16.86 Million ≈ $1.81 Million |
+20.76% |
| 2015-12-31 | Skr13.96 Million ≈ $1.50 Million |
-- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more